oxybutynin has been researched along with Allergy, Peanut in 4 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, E | 1 |
| Fleischer, DM | 2 |
| Chinthrajah, S | 1 |
| Scurlock, AM | 1 |
| Campbell, DE | 2 |
| Green, TD | 2 |
| Bee, KJ | 1 |
| Peillon, A | 1 |
| Ocheltree, T | 1 |
| Sampson, HA | 1 |
| Greenhawt, M | 1 |
| Sussman, G | 1 |
| Bégin, P | 1 |
| Nowak-Wegrzyn, A | 1 |
| Petroni, D | 1 |
| Beyer, K | 1 |
| Brown-Whitehorn, T | 1 |
| Hebert, J | 1 |
| Hourihane, JO | 1 |
| Leonard, S | 1 |
| Chinthrajah, RS | 1 |
| Pongracic, JA | 1 |
| Jones, SM | 1 |
| Lange, L | 1 |
| Chong, H | 1 |
| Wood, R | 1 |
| Cheema, A | 1 |
| Prescott, SL | 1 |
| Smith, P | 1 |
| Yang, W | 1 |
| Chan, ES | 1 |
| Byrne, A | 1 |
| Assa'ad, A | 1 |
| Bird, JA | 1 |
| Kim, EH | 1 |
| Schneider, L | 1 |
| Davis, CM | 1 |
| Lanser, BJ | 1 |
| Lambert, R | 1 |
| Shreffler, W | 1 |
| Mondoulet, L | 1 |
| Dioszeghy, V | 1 |
| Thébault, C | 1 |
| Benhamou, PH | 1 |
| Dupont, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children[NCT02636699] | Phase 3 | 356 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of standardized blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:~ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or~ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).~Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed in the overall population." (NCT02636699)
Timeframe: At Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| DBV712 250 μg | 35.3 |
| Placebo | 13.6 |
The CRD was calculated as the sum of all doses given (including any repeated and partial doses). The median CRD of peanut protein at baseline and Month 12 is presented. Analysis was performed using the modified baseline observation carried forward method to impute missing data at Month 12. (NCT02636699)
Timeframe: Baseline and Month 12
| Intervention | mg (Median) | |
|---|---|---|
| Baseline | Month 12 | |
| DBV712 250 μg | 144.0 | 444.0 |
| Placebo | 144.0 | 144.0 |
"The DBPCFCs to determine ED were performed at screening and Month 12, with each challenge occurring over 2 days. The participant was gradually fed increasing amounts of blinded oral formulas containing either peanut protein (during 1 of the 2 days of the challenge), or without any peanut protein (during the other day of the challenge). A participant was defined as a treatment responder if:~ED was ≥300 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 1), or~ED was ≥1,000 mg peanut protein at Month 12 DBPCFC (for screening ED subgroup 2).~Participants with missing treatment response at Month 12 were imputed as non-responders. The percentage of treatment responders at Month 12 is presented below. Analysis of the difference in response rates between treatment groups is presented in the subsequent statistical analysis table. Analysis was performed for each separate screening ED subgroup." (NCT02636699)
Timeframe: At Month 12
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Screening ED subgroup 1 | Screening ED subgroup 2 | |
| DBV712 250 μg | 39.0 | 34.5 |
| Placebo | 20.0 | 12.2 |
Venous blood samples were drawn to assess peanut-specific IgE levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgE levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline. (NCT02636699)
Timeframe: Baseline and Months 3, 6 and 12
| Intervention | Relative change (percentage) (Median) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| DBV712 250 μg | 78.716 | 39.716 | 2.858 |
| Placebo | 16.964 | 4.605 | -6.919 |
Venous blood samples were drawn to assess peanut-specific IgG4 levels at baseline and Months 3, 6 and 12. The median relative changes from baseline in IgG4 levels for each timepoint are presented. Relative change from baseline=100×(value at the visit-value at baseline)/value at baseline. (NCT02636699)
Timeframe: Baseline and Months 3, 6 and 12
| Intervention | Relative change (percentage) (Median) | ||
|---|---|---|---|
| Month 3 | Month 6 | Month 12 | |
| DBV712 250 μg | 127.778 | 258.491 | 513.487 |
| Placebo | 14.286 | 11.492 | 10.496 |
1 review available for oxybutynin and Allergy, Peanut
| Article | Year |
|---|---|
Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction.
Topics: Administration, Cutaneous; Adolescent; Animals; Child; Child, Preschool; Clinical Trials as Topic; D | 2015 |
2 trials available for oxybutynin and Allergy, Peanut
| Article | Year |
|---|---|
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial.
Topics: Allergens; Arachis; Child; Child, Preschool; Desensitization, Immunologic; Double-Blind Method; Fema | 2020 |
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
Topics: Administration, Cutaneous; Allergens; Arachis; Child; Child, Preschool; Confidence Intervals; Desens | 2019 |
1 other study available for oxybutynin and Allergy, Peanut
| Article | Year |
|---|---|
Trial: Skin Patch for Peanut Allergy Effective in Toddlers.
Topics: Allergens; Child, Preschool; Humans; Peanut Hypersensitivity; Skin Tests; Transdermal Patch | 2023 |